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Introduction
Pentraxins are essential components of the humoral arm of innate 
immunity and represent a family of soluble, multifunctional, pattern 
recognition proteins. Pentraxins are characterized by containing 
a conserved structural motif, the C-terminal pentraxin domain 
which in the case of Pentraxin 3 (PTX3) is coupled to an unrelated 
long N-terminal domain. Pentraxins are involved in acute immune-
inflammatory responses and are divided into short, such as the C - 
reactive protein (CRP), and long pentraxins, such as PTX3 [1]. 
The pentraxin domain is highly conserved in mammals, in lower 
vertebrates and in arthropods. The PTX3 gene is highly conserved 
evolutionary making it possible to address the pathophysiological roles 
of human PTX3 using genetically modified mice [1]. This is not true for 
CRP. Furthermore, PTX3 plasma levels increase rapidly in both human 
and mice peaking at 6-8 hours [2-4] whereas CRP levels increase only 
in humans in 48 hours during the acute-phase response [1].
Evidence is accumulating indicating that increased PTX3 levels are 
also associated to cardiovascular disorders [5] and cancer [6,7]. In the 
last decade, PTX3 has been detected locally at sites of inflammation, 
such as in the myocardium and in the vasculature under different 
pathological conditions and in the tumour microenvironment. In 
addition, increased PTX3 plasma levels have been observed in patients 
as a consequence of rapid synthesis by various cell types. Data from 
animal models suggest that this increase might reflect a feedback 
mechanism involved in dampening an excessive inflammation 
rather than only the consequence of the activation of the immuno-
inflammatory system. On the basis of recent data, we will describe in 
the present review the possible use of PTX3 as a biomarker to improve 
diagnosis and prognosis of cardiovascular disorders and cancer.
PTX3 Involvement in Biological Pathways
PTX3 is the prototypic long pentraxin and is rapidly produced by 
different cell types, such as macrophages, neutrophils, Endothelial Cells 
(ECs), fibroblasts, vascular Smooth Muscle Cells (SMCs) and epithelial 
cells in response to several inflammatory cytokines, such as tumour 
necrosis α and interleukin-1β, ΤRL agonists and microbial components, 
including lipopolysaccharide (LPS) [8-10]. More recently also anti-
inflammatory molecule were shown to modulate PTX3 expression 
such as IL-10 [11], Glucocorticoid Hormones (GCs) [12], and High-
Density Lipoproteins (HDLs), which possess vascular protective 
properties [13]. HDLs induce PTX3 expression in endothelial cells [14] 
by the activating the phosphoinositide 3-kinase (PI3K)/Akt pathway 
through G-coupled lysosphingolipid receptors. This is mimicked by 
sphingosine 1 phosphate (S1P) and others S1P mimetic [14] that are 
physiologically present in HDL and are responsible for some of the 
activities linking HDL to the immune inflammatory response [15].
PTX3 possesses multifunctional properties: similarly to short 
pentraxins, PTX3 recognizes the highly conserved Pathogen-Associated 
Molecular Patterns (PAMPs) expressed by microorganisms [16] and 
interacts with C1q, focolin-2 and Mannose-Binding Lectin (MBL) 
and therefore it modulates the activity of all the three-complement 
pathways [17], thus playing a crucial role in innate immune responses. 
More recently, additional unique roles have been discovered connecting 
PTX3 to inflammation and tissue remodelling. PTX3 competes with 
leukocyte PSGL-1, thus dampening the recruitment and extravasation 
of leukocytes mediated by P-selectin and limiting P-selectin-dependent 
inflammation [18]. Moreover, PTX3 binds with high affinity and 
selectivity Fibroblast Growth Factor (FGF)-2 [19,20], which in turn 
results in the inhibition of the interaction of FGF2 with tyrosine-kinase 
receptors (FGFRs) and Heparin Sulphate Proteoglycans (HSPGs) on 
the surface of endothelial; ECs and SMCs [21]. The FGF/FGFR system 
plays a crucial role not only in FGF2-dependent ECs proliferation [22] 
but also in SMCs proliferation, migration and survival in vitro [23-
26]. These findings suggest that PTX3 is critically involved in both 
angiogenesis and restenosis, two typical phenomena associated to 
cancer and cardiovascular diseases.
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Abstract
Inflammatory mediators may play key roles in both atherosclerosis and cardiovascular disorders and in cancer 
development. Pentraxins are a family of proteins characterized by the structural motif pentraxin domain. Long 
pentraxin 3 (PTX3), a protein that in humans is encoded by the PTX3 gene, is rapidly produced and released by 
several cell types in response to inflammatory stimuli. This review discusses the evidence supporting the role of 
PTX3 in predicting primary cardiovascular events and diagnosis and prognosis of cancer.
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PTX3 as a Cardiovascular Biomarker
While PTX3 deficiency is associated with increased inflammation, 
cardiac damage [4] and atherosclerosis [27], PTX3 overexpression 
reduces carotid restenosis after angioplasty [19,20], thus suggesting 
a protective effect of PTX3 potentially associated with the tuning of 
inflammation in the context of cardiovascular disorders. Despite 
this, the role of PTX3 in human still remains controversial: increased 
plasma levels under diseased conditions might indicate that PTX3 is 
either a bystander of the inflammatory response or a further attempt to 
protection of our body. Indeed PTX3 plasma levels peak within 7.5 hours 
after Myocardial Infarction (MI), as compared to CRP which peaks 
around 50 hours [3]. In MI patients, PTX3 but not CRP independently 
predicted 3 months mortality after adjustment for major risk factors 
and other acute phase proteins [28]. Two large independent clinical 
trials (CORONA and GISSI-HF), showed that PTX3 was consistently 
associated with the outcomes in patients with heart failure and with a 
higher risk of all-cause cardiovascular mortality [29]. 
PTX3 as a Cancer Biomarker
Increased levels of PTX3 have been associated with cancer. PTX3 
was identified by proteomic approaches as an important candidate 
biomarker for prostate cancer [6], lung cancer [7], liposarcomas [30] 
and more recently pancreatic carcinoma [31].
The role of PTX3 in cancer progression remains unknown. 
Molecular studies indicated that PTX3 exerts an anti-tumoral activity 
in prostate cancer by inhibiting FGF2/FGF8b-dependend angiogenesis 
[32,33], potentautocrine and paracrine activities on cancer cells that 
may contribute to tumour progression [34]. The FGF-binding domain 
was identified in the PTX3 N-terminus by monoclonal antibodies and 
surface plasmon resonance analysis [20], while TSG6, the secreted 
product of tumour necrosis factor-stimulated gene, was shown to revert 
the inhibitory effects exerted by PTX3 on FGF2-dependent angiogenesis 
through the interaction with the N-terminal domain of PTX3 [35]. 
Indeed, overexpression of the PTX3 N-terminus strongly inhibits the 
tumorigenic activity of TRAMP (Transgenic Adenocarcinoma Mouse 
Prostate)-C2 transfectants, whereas overexpression of the C-terminus 
has only a minor effect on tumour growth [32]. Although, PTX3 
expression appears to be significantly down-regulated in various human 
prostate cancer datasets [36], a recent paper by Kondo et al. [31] found 
a strong correlation between pentraxin family member expression 
and prognosis of pancreatic carcinoma. The authors propose that 
pentraxin family members, especially PTX3, may be used as promising 
biomarkers in the prognosis of pancreatic carcinoma patients. 
Given the strong correlation between impaired immune system 
activity and cancer, the possibility that increased PTX3 plasma levels 
are correlated to the immune-inflammatory response during cancer, 
similar to what reported in cardiovascular disorders [37], cannot be 
excluded. 
Interestingly, in contrast with data obtained in prostate cancer, 
recent data suggest that PTX3 promotes tumour progression by 
preventing the phagocytosis of tumour cells induced by tumour-
associated macrophages in nasopharyngeal carcinoma [38]. This 
suggests that PTX3 may be a key pro-tumorigenic player in the tumour 
microenvironment.
Several studies suggest that PTX3 is a potential cancer biomarker. 
By using proteomic approach five candidate biomarkers were found 
elevated in serum of lung cancer patients [39]. PTX3 is among these 
candidates and it was also identified as a candidate prostate [6] and 
breast [40] cancer biomarker by using a similar approach. Subsequent 
work has validated PTX3, but not other candidates, in a large cohort 
of lung carcinoma patients and controls [3]. Indeed, PTX3 serum 
elevation occurred in 50% of patients and correlated with the stage 
disease. PTX3 elevations in serum of lung cancer patients are associated 
with inflammation and cancer cell apoptosis around the tumour 
microenvironment.
Recently, PTX3 has been found to be secreted by several pancreatic 
carcinoma cell lines [13]. In addition, secreted PTX3 has been shown 
to promote cell migration in a concentration-dependent manner. 
Evaluation of clinical blood samples for pancreatic carcinoma patients 
revealed a strong correlation between blood PTX3 level and prognosis of 
the disease. Furthermore, the examination of the relationship between 
PTX3 and other pro-inflammatory mediators expression indicated 
that PTX3 is positively correlated with levels of CRP, interleukin-6 and 
macrophage-inhibitory factor. In a more recent study, the expression 
of PTX3 in gliomas was assessed by immunohistochemistry [41]. 
PTX3 expression differed across low and high-grade tumours based on 
histopathological diagnosis and clinical severity, positively correlating 
with tumour grade and severity. 
Conclusions
PTX3 is an emerging biomarker with application in several 
pathological conditions including cardiovascular disorders and cancer. 
Nevertheless, more evidence is required in order to validate PTX3 
as a biomarker with clinical utility either alone or as a member of a 
biomarker panel. Although the accumulating data pave the road for 
investigating the relevance of PTX3 as prognostic marker in different 
cancer conditions and in larger cohorts, several open questions remain: 
Are PTX3 plasma levels affected by cancer treatment? Are these 
changes related to the prognosis? Does PTX3 play a protective role 
in cancer similar to what reported in vitro and in animal studies for 
cardiovascular diseases? To what extent the ability of PTX3 to dampen 
FGF response contribute to limit cancer progression? 
Answers to these questions and future studies on PTX3 expression 
in tissues and cells critically involved in both cardiovascular diseases 
and cancer, such as macrophages, will contribute to improve our 
understandings on the role of PTX3.
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